Bmx (Bone marrow kinase in chromosome X), also known as Etk, is a member of the Tec family of nonreceptor tyrosine kinases. Bmx is expressed mainly in arterial endothelia and in myeloid hematopoietic cells. Bmx regulates ischemia-mediated arteriogenesis and lymphangiogenesis, but its role in tumor angiogenesis is not known. In this study, we characterized the function of Bmx in tumor growth using both Bmx knockout and transgenic mice. Isogenic colon, lung, and melanoma tumor xenotransplants showed reductions in growth and tumor angiogenesis in Bmx gene-deleted ( À/À ) mice, whereas developmental angiogenesis was not affected. In addition, growth of transgenic pancreatic islet carcinomas and intestinal adenomas was also slower in Bmx À/À mice. 
Introduction
Cell differentiation and growth responses are commonly mediated by protein tyrosine phosphorylation, which constitutes a major signaling process in several physiologic states (1) . Tyrosine kinases are of particular interest because many of them are activated and play critical roles in the pathogenesis of cancer (2) .
Bone marrow kinase in chromosome X (Bmx) belongs to the Tec family of nonreceptor/cytoplasmic tyrosine kinases that also includes Btk, Tec, Txk, and Itk (3) . Tec family kinases are predominantly expressed in cells of hematopoietic origin, and also Bmx was originally identified in bone marrow cells (3) . Receptors on bone marrow cells can activate downstream signaling pathways in part via various receptor-associated cytoplasmic tyrosine kinases, including Bmx (4, 5) .
Apart from the myeloid cell lineage, abundant Bmx expression is detected in the endocardium and in arterial endothelia starting embryonic day (E)10.5 to E12.5 (6) . Bmx deletion does not result in any obvious phenotype (6) , suggesting redundancy where other members of this gene family compensate for Bmx functions during development. However, in further studies that aimed at looking into the role of Bmx in pathologic processes, Bmx overexpression in epidermal keratinocytes in the K14-Bmx mice was shown to induce skin hyperplasia, activate a number of inflammatory pathways, and to promote angiogenesis and wound healing (7) .
Angiogenesis is needed for tumor growth beyond a few cubic millimeters in size (8) . Neovascularization in tumors is promoted by VEGF secreted by tumor cells in response to intratumoral hypoxia (9) . Overexpressed Bmx interacts with VEGF and angiopoietin receptors (VEGFR and Tie; ref. 6) . Bmx was furthermore shown to regulate tumor necrosis factor receptor 2-(TNFR2-) and VEGFR2-mediated angiogenic signals in mice undergoing ischemia-induced arteriogenesis and angiogenesis (10, 11) . A recent study suggested that Bmx is also involved in lymphangiogenesis (12) . More detailed analysis of inflammatory signals in Bmx-deficient mice indicated that Bmx was required for full phosphorylation of the mitogen-activated protein kinases (MAPK) p38 and JNK (13) .
Although recent reports have suggested that Bmx is involved in prostate cancer and glioblastoma growth (14, 15) , little is known about Bmx in tumor biology. Here, we have used Bmx gene-deleted mice (6) and K14-Bmx transgenic mice (7) to explore the function of Bmx in tumor growth.
Materials and Methods

Mice
Eight-to 12-week-old Bmx knockout (KO), heterozygous (HT), and wild-type (WT) female mice, or KO and WT male mice of C57Bl/6J and BALB/c backgrounds as well as transgenic K14-Bmx (TG) male mice and the FVB/N WT littermates were used in the experiments. Apc min/þ mice were obtained from the Jackson Laboratory (Bar Harbor; stock no. 002020). RIP1-Tag2 mice (16) were a kind gift from Dr. Gerhard Christofori, University of Basel, Switzerland. The National Board for Animal Experiments at the Provincial State Office of Southern Finland approved all experiments conducted in Finland. All mouse studies conducted in the United States were approved by the Institutional Animal Care and Use Committee of the Yale University School of Medicine. All experiments were conducted in accordance with the legislation about the humane care and use of laboratory animals.
Tumor cell lines and cell culture
Luciferase tagged B16-F10 melanoma cells were obtained from Caliper Life Sciences Inc., and the cells (used in passages below 30) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin (100 mg/mL), and 10% FBS (PromoCell). Lewis lung carcinoma (hereafter LLC) and CT26. WT colon carcinoma cells were purchased from American Type Culture Collection (Manassas, VA) and maintained in complete DMEM and RPMI-1640 medium, correspondingly.
Syngenic tumor assays
CT26.WT cells (5 Â 10 5 cells/mouse, n ¼ 8-10 tumors/ group, 4 experiments), syngenic in the BALB/c background, or B16-F10 (1 Â 10 6 cells/mouse, n ¼ 8-10 tumors/group, 4 experiments) or LLC cells (3 Â 10 6 cells/mouse, n ¼ 8-10 tumors/group, 4 experiments), syngenic in the C57Bl/6J background, were injected into the abdominal subcutis of Bmx À/À and age-matched control mice under anesthesia with ketamine (Ketalar; Pfizer) and xylazine (Rompun vet; Bayer Healthcare). After the establishment of the tumors during the first few days, the primary tumor growth rates were followed by measurements of the height, width, and depth of the tumors with a digital caliber every second day. At the end point, the tumors and the regional (inguinal) lymph nodes were excised, weighed, analyzed ex vivo in 3 dimensions for tumor diameters, and processed for histology. The tumor volumes were then calculated with the formula (height Â width Â depth)/2 and statistically quantified. For bioluminescent imaging analysis, tumor cells were injected bilaterally s.c. into the abdominal flanks of the Bmx À/À and age-matched Bmx þ/þ mice, and the bioluminescence was followed thereafter for 10 days by in vivo bioluminescent optical imaging as described in the Supplementary Materials.
Analysis of tumor vascular perfusion
Fluorescently conjugated Lycopersicon esculentum lectin (100 mL, 1 mg/mL; Vector Laboratories) was administered intravenously. After 5 minutes, the mice were sacrificed and the tumors were excised, fixed with 4% paraformaldehyde (PFA), and processed for further histologic analysis.
Immunohistochemical staining and b-galactosidase staining of tumors
The protocols are detailed in Supplementary Materials.
Microscopy
Bright-field sections were viewed with a Leica DM LB microscope (Leica Microsystems) and images were captured with an Olympus DP50 color camera (Olympus Soft Imaging Solutions GMBH). Immunofluorescent images were taken with a Zeiss Axioplan 2 microscope (Carl Zeiss AG) as detailed in the Supplementary Materials.
Isolation and stimulation of murine blood vascular endothelial cells
The murine blood vascular endothelial cells were isolated from cardiac auricles of 8 mice from each genotype, as described (17) .
RIP1-Tag2 pancreatic tumor model
The RIP1-Tag2 mice deficient of Bmx expression were obtained by crossing the RIP1-Tag2 mice (16) (18) . Tumor incidence (percentage of mice with a tumor) and cumulative tumor multiplicity [number of papillomas divided by the total number of mice alive at the time when the first mouse was removed from the experiment because of a papilloma size >10 mm in diameter or macroscopic squamous cell carcinoma (SCC)] were recorded and tumor size was measured with a digital caliper once a week. Inguinal, axillary, and brachial lymph nodes from the micebearing macroscopically malignant tumors were evaluated histopathologically for the presence of metastases.
Western blot analysis
Blood vascular endothelial cells isolated from Bmx KO and WT mice starved in 0.5% serum-containing endothelial cell medium were stimulated with VEGF (50 ng/mL; produced by Dr. Michael Jeltsch, University of Helsinki, Finland) for 15 minutes or untreated, and processed for Western blot analysis as described in Supplementary Materials.
Statistical analysis
Values are indicated as mean AE SEM. Statistical analysis was conducted with unpaired t test for comparison of 2 groups or 2-way ANOVA followed by Tukey post hoc test for multiple comparisons. Fisher exact test was used for statistical analysis of metastasis occurrence. All statistical tests were 2-tailed. Differences were considered statistically significant at P < 0.05. 
Results
Impaired growth of isogenic B16-F10 melanoma in
Bmx is expressed in the peritumoral arteries
To localize Bmx expression in tumor-bearing mice, B16-F10 melanoma and CT26.WT colon carcinoma xenografts excised from the Bmx À/À mice were stained for b-galactosidase. The blue-stained b-galactosidase marker is expressed in place of Bmx, indicating the sites of native Bmx expression. As shown by analysis of both whole mounts and histologic sections, Bmx was abundantly expressed in the preexisting peritumoral arteries surrounding the subcutaneously implanted tumor tissue in the abdominal area ( Fig. 2A) . 
Bmx deficiency in host reduces tumor angiogenesis and vascular perfusion
To analyze if Bmx in host-derived tissues influences tumor perfusion via blood vessels, fluorescently labeled Lycopersicon esculentum lectin was systemically administered into the tumor-bearing mice before the excision of the CT26.WT colon carcinoma tumors. Comparison of the lectin and PECAM-1 staining showed a moderate reduction of tumor vascular perfusion and decreased vascular density in the Bmx À/À mice ( Fig. 3A and B) . The intratumoral vascular lumen area was decreased also in B16-F10 melanomas excised from the Bmx À/À mice (data not shown). Increased tumor necrosis and decreased density of smooth muscle actin positive cells lining the vessels was observed in the Bmx À/À mice ( Fig. 3C and D) .
The density of Ki67 antigen-positive proliferating cells was reduced in the Bmx À/À mice as well ( Fig. 3C and D) . However, no change was detected in the infiltration of CD45, Gr-1, CD11b, or F4/80 positive inflammatory cells (Fig. 3C and D and data not shown). Taken together, these results suggested that host Bmx contributes to signals for efficient tumor angiogenesis, but not inflammatory cell recruitment into the tumor.
Increased skin tumor growth and angiogenesis in transgenic K14-Bmx mice
We also evaluated the effects of Bmx on tumor growth by subjecting the transgenic K14-Bmx mice expressing Bmx in basal epidermal cells to the chemical skin carcinogenesis model involving DMBA and TPA treatments. The K14-Bmx mice developed increased numbers of tumors when compared with their WT littermates (Fig. 4A) . Tumor development was somewhat accelerated in the TG mice and the proportion of large tumors (3-10 mm in diameter) was slightly higher in the TG mice at late stage of carcinogenesis (Fig. 4A) . However, both mouse strains reached 100% tumor incidence by week 13. Tumor angiogenesis was augmented in the papillomas and SCCs of the TG mice in comparison with their WT littermates ( Fig. 4B and C) . Consistent with the data obtained from CT26.WT colon carcinomas in Bmx À/À mice, inflammatory cells did not show differences between the K14-Bmx and the WT tumors (data not shown). In this model, Bmx probably not only regulates tumor angiogenesis, but also tumor growth through its expression in the keratinocytes. Taken together, the results from the DMBA-TPA model support the view that Bmx contributes to tumor growth and angiogenesis.
Variable effects on cutaneous tumor growth and angiogenesis in Bmx-deficient mice
To analyze the influence of Bmx deficiency on the development of chemically induced epidermal tumors, Bmx-deficient female and male mice with the age-and gender-matched control mice were subjected to the DMBA-TPA treatments. The rate of tumor initiation was similar between Bmx þ/À and Bmx þ/þ female mice, and slightly, but not significantly, delayed in the Bmx À/À mice ( Supplementary Fig. S1A ). How- Fig. S1B ). This suggests that the genetic loss of Bmx results in a significant growth delay of chemically induced skin tumors in female mice, with suppression of angiogenesis in the tumors that have undergone malignant conversion. However, in the analysis of the same parameters, the Bmx À/0 and Bmx
male mice did not show any significant changes between the genotypes in this tumor model ( Supplementary Fig.  S2A-S2C ). These data indicate that the haploid and homozygous Bmx deletions have different effects on tumor initiation and growth.
Altered tumor metastasis in Bmx-modified mice
We further assessed if Bmx deletion impairs the dissemination of tumor cells from the primary tumor. The lymph nodes of tumor-bearing mice were excised and macroscopically examined for metastases at various time points. The occurrence of melanoma metastases was significantly decreased in Bmx-deficient mice when compared with wildtype mice at 3 and 6 weeks after tumor cell implantation (Fig.  5A ). Lymph nodes from the K14-Bmx and Bmx KO mice and controls bearing macroscopically malignant SCCs were also analyzed at 15, 20, and 25 weeks after the DMBA-TPA treatment. The frequency of tumor metastasis was significantly increased in the K14-Bmx mice when compared with the WT control mice at 20 and 25 weeks (Fig. 5B) , whereas it was decreased in the homozygous Bmx À/À and, unexpectedly, increased in the heterozygous Bmx þ/À female mice in comparison with the Bmx þ/þ mice (data not shown). Consistent with other analyses, no differences were detected in the analysis of dissemination to lymph nodes in the Bmx À/0 and Bmx þ/0 groups (data not shown). These data further support our observations that homozygous and haploid deletion of Bmx has different effects on tumor development.
Delayed growth of Apc
Min/þ intestinal adenomas in Bmx À/À mice
VEGF inhibition has been reported to delay the growth of intestinal adenomas in the transgenic Apc
Min/þ colon carcinoma model (19) . Recently, Toll-like receptor (TLR) signaling and extracellular signal-regulated kinase (Erk) activation were also shown to be essential for the intestinal tumorigenesis in the Apc Min/þ mice (20) . As Bmx has been shown to mediate TLR signals, in particular signals downstream of TLR-4 (21), and interact with MyD88 (22) , an important mediator in Erk signaling (20) , we analyzed the Apc Min/þ phenotype in the Bmx À/À mice. The intestinal adenoma growth was reduced in Bmx-deficient female mice to a statistically significant extent ( Fig. 6A and B) . However, intestinal adenoma growth mice when compared with the RIP1-Tag2 þ/À ; Bmx þ/þ controls at the age of 13.5 weeks (Fig. 6C) . However, Bmx deficiency did not alter RIP1-Tag2-driven oncogenic tumor growth in Bmx À/0 male mice when compared with the RIP1-Tag2 þ/À , Bmx þ/0 control mice ( Supplementary Fig. S2D ).
Phosphorylation of signaling proteins downstream of Bmx in endothelial cells and tumor xenografts VEGF, by binding to its cognate receptor, VEGFR2, mediates angiogenesis during development and in pathologic Cumulative tumor multiplicity in TG mice, n ¼ 16, and in WT mice, n ¼ 18 mice, P ¼ 0.048 at week 25. Tumor incidence: tumor size presented as the percentage of tumors in 3 different size categories, with tumor diameter of 1 to 3 mm, 3 to 7 mm, or 7 to 10 mm. B, representative images of immunohistochemical staining for PECAM-1 in skin papillomas (PAP) and squamous cell carcinomas (SCC) harvested from the TG and WT mice. C, quantification of tumor blood vessel densities. Scale bar, 100 mm; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. Fig. S3A-S3C ).
Discussion
Bmx, a member of Tec family of nonreceptor tyrosine kinases, has been implicated in several cellular processes, including cell differentiation and growth signaling (5, 26) , but a definitive function of Bmx in tumor growth, particularly in tumor angiogenesis, has remained thus far elusive. In this study, we characterized the contribution of Bmx to tumor growth by using genetically modified mice that either lack or overproduce Bmx and a variety of tumor models. By using the Bmx-LacZ knock-in mice, we localized host Bmx expression to arterial vasculature and inflammatory cells associated with the tumor, whereas very little or no expression was detected in the capillaries. These findings are in agreement with previously published data (27, 28) .
In our experiments, loss of Bmx in the host resulted in variably decreased tumor growth in syngeneic tumor models of colon carcinoma, melanoma and non-small cell lung cancer in female mice. Tumor growth in RIP1-Tag2 and Apc
Min/þ transgenic mice was clearly reduced upon homozygous Bmx deletion, suggesting that Bmx expressed in the tumor cells also contributes to tumor growth. On the other hand, when Bmx was overexpressed in epidermal cells, the development of cutaneous carcinomas induced by the DMBA-TPA was accelerated. This is in agreement with studies where Bmx expression in tumor cells was shown to promote the growth of human tumor xenografts in mice (14) . The reason for the failure to reproduce the results obtained in Bmx À/À female mice in Bmx À/0 male mice is as yet unknown to us, but we speculate that Bmx may have haploinsufficient function in male mice that is compensated by some other genetic pathway that we are currently trying to identify. It is interesting to note that Bmx knockdown was recently shown to potently inhibit the STAT3 signaling protein activation, expression of glioblastoma stem cell transcription factors, and growth of glioblastoma stem cell-derived intracranial tumors (15) , and that the STAT5 pathway downstream of Bmx is regulated by female steroid hormones (4, 29) . Bmx is involved in the activation of the NF-kB pathway (13) and in angiogenesis and arteriogenesis downstream of TNFR2 (10, 11, 25, 30) . In cultured endothelial cells lacking Bmx, TNFa-induced phosphorylation of VEGFR2 was attenuated (25) . In light of these data, the recent finding of the coordinated VEGFR2-Bmx activation in TNFR2-mediated growth of renal cell cancer is of interest and warrants further analysis of Bmx in tumor growth and angiogenesis (31) .
To look into the cellular mechanisms underlying the reduced angiogenesis in mice lacking Bmx, we conducted proteomic profiling of a variety of intracellular phosphokinases in isolated vascular endothelial cells stimulated with VEGF. Phosphorylation of Erk was reduced in cells lacking Bmx, especially upon VEGF treatment. This result suggests that the interaction between VEGF/VEGFR2 and Bmx promotes an angiogenic tumor phenotype, perhaps in part via Erk as a downstream target in the vascular endothelium.
In addition to vascular endothelium, myeloid cells form another primary site of endogenous Bmx expression (3, 27) . Because of this, and because of the possibility that Bmx mediates inflammatory signals in the tumors, bone marrow derived cells were investigated in the tumors. The recruitment of leukocytes or macrophages to the tumors was not altered by Bmx deficiency or excess, suggesting that inflammatory signals were not responsible for the tumor phenotype.
We also detected decreased dissemination of B16-F10 melanoma cells into lymph nodes Bmx-deficient mice as well as decreased dissemination of SCCs into lymph nodes in Bmx À/À the DMBA-TPA model, and an increase of lymph node metastasis in the K14-Bmx mice subjected to chemical carcinogenesis protocol. Although the abrogation of tumor cell dissemination may be secondary to the decreased tumor growth or vascularization, previous data have implicated Bmx signals in cell migration (32) (33) (34) . Bmx promotes integrin signaling via binding to focal adhesion kinase (FAK; ref. 33) , and this crosstalk is required for integrin-mediated cell motility (33) . Indeed, Bmx protein levels have been reported to be elevated in carcinoma cells prone to metastasis (33, 35) . Our present data with oncogenic tumor models demonstrate the contribution of Bmx kinase in tumor growth and angiogenesis in vivo. Interestingly, molecular inhibitors targeting Bmx are available (36) , and one of these was reported to inhibit Src-induced cellular transformation in culture (36) . Further studies should evaluate Bmx as a possible target of cancer therapy.
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